Eventide Asset Management - ALX ONCOLOGY HLDGS INC ownership

ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 101 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of ALX ONCOLOGY HLDGS INC
ValueSharesWeighting
Q1 2023$3,005,027
-70.4%
664,829
-26.3%
0.06%
-72.5%
Q4 2022$10,165,540
+17.8%
902,0000.0%0.20%
+17.6%
Q3 2022$8,632,000
-64.1%
902,000
+105.0%
0.17%
-47.4%
Q2 2021$24,056,000
+262.5%
439,950
+388.8%
0.32%
+229.6%
Q1 2021$6,637,00090,0000.10%
Other shareholders
ALX ONCOLOGY HLDGS INC shareholders Q3 2022
NameSharesValueWeighting ↓
venBio Partners LLC 9,699,925$715,272,00067.97%
Logos Global Management LP 3,156,981$232,796,00022.72%
Vivo Capital, LLC 4,220,048$311,186,00010.94%
Foresite Capital Management IV, LLC 785,945$57,956,0006.94%
Foresite Capital Management V, LLC 320,000$23,597,0006.94%
Board of Trustees of The Leland Stanford Junior University 518,822$38,258,0003.38%
Cormorant Asset Management, LP 881,770$65,022,0001.45%
Redmile Group, LLC 978,600$72,162,0001.02%
SPHERA FUNDS MANAGEMENT LTD. 130,351$9,612,0000.74%
Artal Group S.A. 525,000$38,714,0000.68%
View complete list of ALX ONCOLOGY HLDGS INC shareholders